GlassScriptPhysician profile
Richard James Bergeron
NPI 1700323540
$3,848.18
in general payments reported to CMS, 2019-2025
19 companies · $826 in 2025
The $826 reported for 2025 was more than what 77% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $883 · 2022: $812 · 2023: $661 · 2024: $666 · 2025: $826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,104 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,104.31 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $699.02 | 2021-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $601.86 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $568.18 | 2021-2024 | Caplyta |
| Abbvie INC. | $534.77 | 2021-2025 | |
| Corium, LLC | $364.80 | 2021-2025 | Azstarys |
| Alkermes, INC. | $239.97 | 2022-2025 | Aristada, Lybalvi |
| Ironshore Pharmaceuticals INC. | $154.38 | 2022-2024 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $152.15 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $128.54 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $91.47 | 2021-2024 | Rexulti, Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $69.28 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $58.52 | 2023-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $47.55 | 2021-2025 | Austedo Xr, Uzedy |
| Collegium Pharmaceutical, INC. | $39.43 | 2025 | Jornay Pm |
| Abbott Laboratories | $24.73 | 2025 | Freestyle Libre |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $22.99 | 2021 | |
| Tris Pharma INC | $17.59 | 2024 | Dyanavel Xr |
| Indivior INC. | $16.95 | 2021 | |
| Vanda Pharmaceuticals INC. | $16.00 | 2023 | Fanapt, Hetlioz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Bergeron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.